In their article, Heald et al. 1 address the important requirement for insulin assays to be able to detect exogenous insulin. They report that, with the exception of the Mercodia assay, none of the commercial insulin assays in the UK National External QualityAssessment Scheme (UK NEQAS) is able to detect quantitatively the recombinant human insulin, Actrapid s . However, they o¡er no suggestion as to why most insulin assays should fail to detect a molecule that is identical to the circulating protein. Their study was carried out with only one fasting specimen, spiked with 30 pmol/L Actrapid s insulin. Neither imprecision nor the presence of interfering heterophile antibodies in the specimen may have explained the variation in the reported results. (Except for DPC assays, which use a combination of sheep and mouse antibodies, the rest, including the Mercodia assay, use only mouse antibodies.)
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We assessed the ability of BayerAdvia Centaur s (John Radcli¡e Hospital, Oxford, UK) and Dako (Dr K Islam and Ms K Fisher, Diabetes Trials Unit, Oxford University) insulin assays to detect Actrapid s insulin. Dilutions of Actrapid s (10 U/mL, Novo Nordisk) were made either in a solution of 10 mmol/L phosphate-bu¡ered saline (PBS, pH 7.4) that contained 1% bovine serum albumin (BSA) or in serum specimens from fasted patients, none of whom was receiving any exogenous insulin.
In four separate experiments, the Bayer Centaur s method gave recoveries of between 66.6% and 107.5% (mean ¼ 83.7%; SD ¼15.6%) when dilutions of Actrapid s were made in PBS þ BSA (concentration range 27.6--690 pmol/L). The results from one of these experiments, in which three separate pools of serum were also spiked and measured by the Dako method, have been given in Table 1 . The Bayer Centaur s insulin recoveries were not in£uenced by sample matrix. Recoveries by the Dako method were 18.3% (95% con¢dence interval [CI] ¼ 4.8%--31.8%) lower than those by the Bayer method. This bias, however, was not statistically di¡erent from that observed in our previous method comparisons that had shown the Dako method to give endogenous insulin results on average 11.6% (95% CI ¼ 6.6%--16.6%; n ¼ 77; concentration range 7--1520 pmol/L) lower than those obtained by the Bayer Centaur s method.
In a separate experiment, insulin concentrations of two Actrapid s -spiked PBS þ BSA specimens were measured by the Bayer Centaur s method, and dispatched frozen to another laboratory for insulin analysis by the Mercodia method. The results, also given in Table 1 , suggest that the Bayer method is capable of detecting Actrapid s insulin at least as well as the Mercodia method.
The data presented here suggest some under-recovery of Actrapid s by both the Bayer Centaur s and the Dako assays. Importantly, however, these results should be viewed in the light of the expected inaccuracies in making greater than one-million-fold dilutions of Actrapid s for the recovery experiments, the bias between di¡erent assay results as observed from the UK NEQAS data, and the small di¡erences in factors used to convert units of insulin into moles. In addition, we have data (not presented) to show that in the absence of added protein, very large amounts of Actrapid s insulin adsorb relatively rapidly to laboratory plastic-ware, diminishing the amount available for detection by the assay. Notwithstanding these limitations, our ¢ndings suggest that the Bayer Centaur s and the Dako insulin methods can detect Actrapid s insulin acceptably. In the assessment of insulin results that do not ¢t clinical ¢ndings in patients with type-I diabetes, it is also important that consideration be given to anti-insulin antibodies, which are prevalent in a signi¢cant number of these patients. 2 Depending on the a⁄nity of these antibodies relative to those employed in the assay, and whether a one-site competitive or a two-site immunometric assay is used, antiinsulin antibodies can produce spuriously high as well as low results. 3, 4 Alireza Morovat Urine free cortisol analysis by automated immunoassay and high-performance liquid chromatography for the investigation of Cushing's syndrome: a comment on the paper of Ching et al.
I read with great interest the paper of Ching et al. 1 who compared a widely used immunoassay method for urine free corticoids with a high-performance liquid chromatography (HPLC) method for the investigation of Cushing's syndrome (CS). They stated 'Urine free cortisol is useful in the investigation of CS as it re£ects the integrated cortisol production rate. However, the question remains whether an accurate and speci¢c urine cortisol determination, such as that obtained by HPLC, necessarily improved the diagnosis of CSyIn conclusion, we report that UFC analysis using an immunoassay analyser provides results, which serve as valid simple initial test in the investigation of CS' (p 407). Apart from the fact that their latter conclusion is controversial (for discussion, see Findling and Ra¡ 2 ), a major shortcoming of their paper is the fact that authors marginalized the possible relation between free cortisol/corticoid excretion and urine volume that was reported by Fenske 3 and previous investigators. 4--7 In addition, interpretation of their urinary free cortisol/corticoid values may be even more di⁄cult if £uid intake (resulting in increased urine volume) was not strictly controlled on the day of urine sampling, since an increased urine volume in the morning (zenith of adrenal activity 8 ) presumably has a more pronounced e¡ect on urinary free cortisol/corticoid excretion than an increased urine volume in the evening (nadir of adrenal activity 8 ).
In conclusion, patients should strictly control their £uid intake when they collect 24-h urines for analysis of urinary free corticoids, and investigators should consider urine volume as an important pre-analytical parameter.
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